Sign In
Buy CAPR
$25.33
-0.680 (-2.61%)
At Close: Jun 10, 2026
The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review
12:00am, Sunday, 15'th Mar 2020
The biopharma space bled along with the rest of the market and COVID-19 levered biotechs weren't spared either.
Biogen Inc (NASDAQ: BIIB) was in the news for all wrong...
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
Capricor Therapeutics to Present Fourth Quarter and Full Year 2019 Financial Results and Recent Corporate Update on March 18
08:30pm, Wednesday, 11'th Mar 2020
Capricor Therapeutics (CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare
The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment
12:03pm, Wednesday, 11'th Mar 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 10) * Arcutis Biotherapeutics Inc (NASDAQ: ARQT) * A
Does Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Pay Reflect Performance?
11:01am, Tuesday, 10'th Mar 2020
Linda Marbán became the CEO of Capricor Therapeutics, Inc. (NASDAQ:CAPR) in 2010. First, this article will compare CEO...
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 9.)
Arcutis...
